

Express Mail No. EV 641 736 666 US

| | | |
|---|----------------------|---|
| <p align="center">INFORMATION DISCLOSURE STATEMENT</p> <p>Address to: Mail Stop Box PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p> | Attorney Docket | RICE-050 |
| | First Named Inventor | MACKAY, CHARLES REAY |
| | Application Number | 10/584,480 |
| | Confirmation No. | 3065 |
| | Filing Date | Not yet assigned |
| | Group Art Unit | Not yet assigned |
| | Examiner Name | Not yet assigned |
| | Title: | "TRANSGENIC NON-HUMAN MAMMAL COMPRISING A POLYNUCLEOTIDE ENCODING HUMAN OR HUMANIZED C5AR " |

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. RICE-050 may be charged thereon.


Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date:

April 17, 2007

By:



Carol L. Francis, Ph.D.
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|----------------------|------------------------|----------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 10/584,480 | | |
| | | Filing Date | Not yet assigned | | |
| | | First Named Inventor | MACKAY, CHARLES REAY | | |
| | | Art Unit | Not yet assigned | | |
| | | Examiner Name | Not yet assigned | | |
| Sheet | 2 | of | 2 | Attorney Docket Number | RICE-050 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| /M.W./ | | Gerard, N. P. et al. Human chemotaxis receptor genes cluster at 19q13.3-13.4. characterization of the human C5a receptor gene. <i>Biochemistry</i> (1993), 32: 1243-1250. | |
| /M.W./ | | Höpken, U.E. et al. The C5a chemoattractant receptor mediates mucosal defence to infection, <i>Nature</i> (1996), 383: 86-89. | |
| /M.W./ | | Heller et al. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. <i>The Journal of Immunology</i> (1999) 163: 985-994. | |
| /M.W./ | | Köhl, J. et al. Anaphylatoxins and infectious and non-infectious inflammatory diseases. <i>Molecular Immunology</i> (2001) 38: 175-187. | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|-------------------------------|--------------------|------------|
| Examiner Signature | /Michael Wilson/ (09/18/2008) | Date Considered | 09/18/2008 |
|-----------------------|-------------------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.